BUSINESS
Terumo Aims at Annual Sales of 1-2 Billion Yen for HeartSheet within 5-10 Years
Terumo Corporation expects to turn its regenerative medicine product HeartSheet into a product with annual sales of one to two billion yen within five to 10 years if it obtains additional indications and a more-efficient transplantation process is developed. Terumo…
To read the full story
Related Article
- Japan Grants 1st Conditional Approval to Terumo’s HeartSheet
September 24, 2015
BUSINESS
- Chugai Licenses RAF-MEK Molecular Glue to InxMed
September 30, 2026
- OB-GYN Chief Hopes for April 2027 NIP Addition of RSV Antibodies
September 30, 2026
- KM Biologics Eyes Plasma Product Capacity Expansion with Govt Backing
September 30, 2026
- Japan Needs to Boost COVID Vaccine Uptake, Expert Says
September 30, 2026
- Toho, Reprocell Tie Up on Cell Therapy Distribution in Japan
September 30, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…





